RT Journal Article
SR Electronic
T1 POST-ACUTE SEQUELAE AND ADAPTIVE IMMUNE RESPONSES IN PEOPLE LIVING WITH HIV RECOVERING FROM SARS-COV-2 INFECTION
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.10.22270471
DO 10.1101/2022.02.10.22270471
A1 Peluso, Michael J.
A1 Spinelli, Matthew A.
A1 Deveau, Tyler-Marie
A1 Forman, Carrie A.
A1 Munter, Sadie E.
A1 Mathur, Sujata
A1 Tang, Alex F.
A1 Lu, Scott
A1 Goldberg, Sarah A.
A1 Arreguin, Mireya I.
A1 Hoh, Rebecca
A1 Chen, Jessica Y.
A1 Martinez, Enrique O.
A1 Chenna, Ahmed
A1 Winslow, John W.
A1 Petropoulos, Christos J.
A1 Sette, Alessandro
A1 Weiskopf, Daniella
A1 Kumar, Nitasha
A1 Lynch, Kara L.
A1 Hunt, Peter W.
A1 Durstenfeld, Matthew S.
A1 Hsue, Priscilla Y.
A1 Kelly, J. Daniel
A1 Martin, Jeffrey N.
A1 Glidden, David V.
A1 Gandhi, Monica
A1 Deeks, Steven G.
A1 Rutishauser, Rachel L.
A1 Henrich, Timothy J.
YR 2022
UL http://medrxiv.org/content/early/2022/02/14/2022.02.10.22270471.abstract
AB Background Limited data are available on the long-term clinical and immunologic consequences of SARS-CoV-2 infection in people with HIV (PWH).Methods We measured SARS-CoV-2 specific humoral and cellular immune responses in people with and without HIV recovering from COVID-19 (n=39 and n=43, respectively) using binding antibody, surrogate virus neutralization, intracellular cytokine staining, and inflammatory marker assays. We identified individuals experiencing symptomatic post-acute sequelae of SARS-CoV-2 infection (PASC) and evaluated immunologic parameters. We used linear regression and generalized linear models to examine differences by HIV status in the magnitude of inflammatory and virus-specific antibody and T cell responses, as well as differences in the prevalence of PASC.Results Among PWH, we found broadly similar SARS-CoV-2-specific antibody and T cell immune responses as compared with a well-matched group of HIV-negative individuals. PWH had 70% lower relative levels of SARS-CoV-2 specific memory CD8+ T cells (p=0.007) and 53% higher relative levels of PD-1+ SARS-CoV-2 specific CD4+ T cells (p=0.007). Higher CD4/CD8 ratio was associated with lower PD-1 expression on SARS-CoV-2 specific CD8+ T cells (0.34-fold effect, p=0.02). HIV status was strongly associated with PASC (odds ratio 4.01, p=0.008), and the proportion of PD-1+ CD4+ T cells and levels of certain inflammatory markers (IL-6, TNF-alpha, and IP-10) were associated with persistent symptoms.Conclusions We identified potentially important differences in SARS-CoV-2-specific CD4+ and CD8+ T cells that might have implications for long-term immunity conferred by natural infection. HIV status strongly predicted the presence of PASC. Larger and more detailed studies of PASC in PWH are urgently needed.Competing Interest StatementAC, JWW, and CJP are employees of Monogram Biosciences. AS is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. TJH reports grants from Merck and Co. and Bristol-Myers Squibb outside the submitted work. The remaining authors have no conflicts related to the current work to report.Funding StatementThis work was supported by the National Institutes of Health (R01 AI141003, R01 AI158013, T32 AI60530, K23 AI157875, and K23 AI135037), and the UCSF/Gladstone Center for AIDS Research (CFAR). MJP received funding from the UCSF Resource Allocation Program and the CFAR Rapid COVID grant program. This work has been supported by NIH contract 75N93019C00065 (A.S, D.W).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UCSF institutional review board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.